argenx

argenx SE is a commercial-stage, global biopharmaceutical company dedicated to improving the lives of patients suffering from severe autoimmune diseases. Founded in 2008, the company operates with a mission to develop and deliver innovative immunology therapies that can transform the quality of life for these patients. With its headquarters based in Amsterdam, the Netherlands, argenx has established a significant presence on a global scale, including critical operations in the U.S., Japan, and Belgium. Innovation is at the core of argenx's strategy, driving a robust pipeline of differentiated therapies such as efgartigimod, the first approved FcRn blocker in the U.S. and Europe for the treatment of generalized myasthenia gravis (gMG). This product is a testament to argenx's commitment to co-creation, a principle that fosters collaboration with leading academic researchers through its Immunology Innovation Program (IIP).

The IIP serves as the engine for discovery at argenx, translating cutting-edge research into clinical advancements. The company’s emphasis on antibody engineering includes proprietary technologies like the SIMPLE ANTIBODY™ platform and a variety of mutations designed to enhance therapeutic properties and effectiveness. argenx also focuses on empowering its teams through a culture of collaboration and trust, recognizing that collective effort is crucial in addressing the complexities of autoimmune diseases. Overall, argenx stands at the forefront of biopharmaceutical innovation, holding a steadfast commitment to harnessing science to improve patient outcomes.